Dyne Therapeutics Inc (NASDAQ: DYN) is 173.76% higher on its value in year-to-date trading and has touched a low of $6.40 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DYN stock was last observed hovering at around $34.34 in the last trading session, with the day’s gains setting it 2.07%.
Currently trading at $36.41, the stock is -4.77% and -11.51% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.43 million and changing 6.03% at the moment leaves the stock 27.37% off its SMA200. DYN registered 269.27% gain for a year compared to 6-month gain of 30.46%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -22.23% loss in the last 1 month and extending the period to 3 months gives it a 12.41%, and is 10.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.89% over the week and 6.60% over the month.
Dyne Therapeutics Inc (DYN) has around 141 employees, a market worth around $3.66B and $0.00M in sales. Distance from 52-week low is 468.91% and -23.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.36%).
The EPS is expected to grow by 24.64% this year
269.0 institutions hold shares in Dyne Therapeutics Inc (DYN), with institutional investors hold 113.36% of the company’s shares. The shares outstanding are 100.40M, and float is at 75.02M with Short Float at 9.15%. Institutions hold 112.80% of the Float.
The top institutional shareholder in the company is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 8.02 million shares valued at $283.03 million. The investor’s holdings represent 9.8961 of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 7.85 million shares valued at $276.86 million to account for 9.6804 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.39 million shares representing 9.1148 and valued at over $260.69 million, while RTW INVESTMENTS, LP holds 7.8811 of the shares totaling 6.39 million with a market value of $225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
The most recent transaction is an insider sale by HIGH SUSANNA GATTI, the company’s Chief Operating Officer. SEC filings show that HIGH SUSANNA GATTI sold 8,976 shares of the company’s common stock on Sep 18 ’24 at a price of $34.41 per share for a total of $0.31 million. Following the sale, the insider now owns 0.13 million shares.
Dyne Therapeutics Inc disclosed in a document filed with the SEC on Sep 18 ’24 that Scalzo Richard William (SVP, Head of Finance & Admin.) sold a total of 1,390 shares of the company’s common stock. The trade occurred on Sep 18 ’24 and was made at $34.55 per share for $48024.0. Following the transaction, the insider now directly holds 98568.0 shares of the DYN stock.
Still, SEC filings show that on Sep 18 ’24, Beskrovnaya Oxana (Chief Scientific Officer) disposed off 2,339 shares at an average price of $34.55 for $80812.0. The insider now directly holds 140,375 shares of Dyne Therapeutics Inc (DYN).
